References
- GaBI Journal Editor. USA and Europe differ in interchangeability of biosimilars. Generics Biosimilars Initiat J. 2017;6(4):183–184.
- USFDA. Draft guidance for industry: considerations in demonstrating interchangeability with a reference product [Internet]. January 2017. Date Cited November 20, 2018. Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM537135.pdf
- Christl L. Considerations in demonstrating interchangeability with a reference product – FDA draft guidance for industry. Presentation at: DIA 2018 Global Annual Meeting; 2018 Jun 25. Meeting took place in Boston, MA, USA.
- Cohen HP, Blauvelt A, Rifkin RM, et al. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs. 2018;78(4):463–478.
- USFDA. The concept of interchangeability [Internet]. Date Cited November 20, 2018 Year 2018 (FDA published to youtube on May 22, 2018). Available from: https://www.youtube.com/watch?v=ooP7djSgtBE&t=0s&list=PLey4Qe-UxcxbFinyBSntx188r2lvxqxak&index=5
- USFDA. Prescribing biosimilar products [Internet]. Date Cited November 20, 2018 Year created according to document properties was 2017. Available from: https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/UCM581341.pdf
- EBE, EFPIA and IFPMA. Position paper: considerations for physicians on switching decisions regarding biosimilars [Internet]. Date Cited November 20, 2018. September 2017. Available from: https://www.efpia.eu/media/26040/annex-1-considerations-for-switching-decisions_biosimilars-and-rbps-final.pdf